Wockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of global antibiotic trial for innovations like WCK5222 and WCK4873.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.